November 6, 2026 at 8:23 AM
Korrektur: Die zweite Kundgebung ist in Bingen am Rhein, nicht Ingelheim.
November 7, 2026 at 2:39 PM
Korrektur: Die zweite Kundgebung ist in Bingen am Rhein, nicht Ingelheim.
Mein Tip: Restaurant Capri in Ingelheim.
November 8, 2026 at 8:39 PM
Mein Tip: Restaurant Capri in Ingelheim.
Aktuell stehen 11 Neonazis der NPD in Sprendlingen (Rheinhessen) und fordern die Streichung der Paragraphen 86 und 130 aus dem Grundgesetz (sic). Von allen Seiten lauter Gegenprotest. Im Anschluss wollen sie weiter nach Ingelheim am Rhein.
November 7, 2026 at 2:19 PM
Aktuell stehen 11 Neonazis der NPD in Sprendlingen (Rheinhessen) und fordern die Streichung der Paragraphen 86 und 130 aus dem Grundgesetz (sic). Von allen Seiten lauter Gegenprotest. Im Anschluss wollen sie weiter nach Ingelheim am Rhein.
Boehringer Ingelheim ha organizado dos acciones formativas, en Bilbao y Alicante, para abordar un problema muy común en las clínicas veterinarias: gestionar correctamente el cobro de sus servicios
Nueve de cada diez veterinarios encuestados reconocen haber dejado algún servicio sin cobrar
Boehringer Ingelheim ha organizado dos acciones formativas, en Bilbao y Alicante, para abordar un problema muy común en las clínicas veterinarias: gestionar correctamente el cobro de sus ser ...
mlibr.es
November 6, 2026 at 6:04 PM
Boehringer Ingelheim ha organizado dos acciones formativas, en Bilbao y Alicante, para abordar un problema muy común en las clínicas veterinarias: gestionar correctamente el cobro de sus servicios
Boehringer Ingelheim is paying $358M upfront for six preclinical ADCs and T cell engagers from China's Sino, in a deal that could top $7B.
Boehringer Ingelheim strikes $7B backloaded ADC, TCE cancer deal with China's Sino
Germany's Boehringer Ingelheim is further planting its stake in China, teaming up with Sino Biopharmaceutical in a cancer drug development deal that could balloon past $7 billion.
endpoints.news
November 4, 2026 at 8:16 PM
Boehringer Ingelheim is paying $358M upfront for six preclinical ADCs and T cell engagers from China's Sino, in a deal that could top $7B.
Mitte Januar in der Nähe von Ingelheim und an Namibia interessiert? Dann gäbe es dieses Seminar...
www.wbz-ingelheim.de/fridtjof-nan...
www.wbz-ingelheim.de/fridtjof-nan...
Namibia. Von der kolonialen Vergangenheit zur Gegenwart / WBZ Ingelheim
Das Seminar nimmt die deutsche Kolonialgeschichte zum Ausgangspunkt einer Auseinandersetzung mit der Geschichte und den Entwicklungsperspektiven des heutigen Namibia.
www.wbz-ingelheim.de
November 9, 2026 at 9:06 AM
Mitte Januar in der Nähe von Ingelheim und an Namibia interessiert? Dann gäbe es dieses Seminar...
www.wbz-ingelheim.de/fridtjof-nan...
www.wbz-ingelheim.de/fridtjof-nan...
Andreas Barner – stellvertretender Vorsitzender (Ex-Chef Boehringer Ingelheim, Aufsichtsratsvorsitzender der FAZ GmbH)
Monika Hermanns (Ex-Bundesverfassungsrichterin)
Peter M. Huber (Ex-Bundesverfassungsrichter, Ex-Innenminister Thüringen)
Monika Hermanns (Ex-Bundesverfassungsrichterin)
Peter M. Huber (Ex-Bundesverfassungsrichter, Ex-Innenminister Thüringen)
November 3, 2026 at 10:23 AM
Andreas Barner – stellvertretender Vorsitzender (Ex-Chef Boehringer Ingelheim, Aufsichtsratsvorsitzender der FAZ GmbH)
Monika Hermanns (Ex-Bundesverfassungsrichterin)
Peter M. Huber (Ex-Bundesverfassungsrichter, Ex-Innenminister Thüringen)
Monika Hermanns (Ex-Bundesverfassungsrichterin)
Peter M. Huber (Ex-Bundesverfassungsrichter, Ex-Innenminister Thüringen)
Sino Biopharm Surges After Striking Over USD7 Billion Cancer Drug Deal With Boehringer Ingelheim
www.yicaiglobal.com/news/sino-bi...
www.yicaiglobal.com/news/sino-bi...
Sino Biopharm Soars After Striking Over USD7 Billion Cancer Drug Deal With Boehringer Ingelheim
www.yicaiglobal.com
November 7, 2026 at 2:30 AM
Sino Biopharm Surges After Striking Over USD7 Billion Cancer Drug Deal With Boehringer Ingelheim
www.yicaiglobal.com/news/sino-bi...
www.yicaiglobal.com/news/sino-bi...
🏥 Boehringer Ingelheim and Sino Biopharmaceutical Sign $7.4B Oncology Deal
Boehringer Ingelheim has committed up to $7.358 billion in a second major oncology collaboration with Sino Biopharmaceutical.
🔗 Read the full story on GazeWire
#Health #Biotech #Crispr #GazeWire
Boehringer Ingelheim has committed up to $7.358 billion in a second major oncology collaboration with Sino Biopharmaceutical.
🔗 Read the full story on GazeWire
#Health #Biotech #Crispr #GazeWire
🏥 Boehringer Ingelheim and Sino Biopharmaceutical Sign $7.4B Oncology Deal
Boehringer Ingelheim has committed up to $7.358 billion in a second major oncology collaboration with Sino Biopharmaceutical.
gazewire.com
November 6, 2026 at 5:45 AM
🏥 Boehringer Ingelheim and Sino Biopharmaceutical Sign $7.4B Oncology Deal
Boehringer Ingelheim has committed up to $7.358 billion in a second major oncology collaboration with Sino Biopharmaceutical.
🔗 Read the full story on GazeWire
#Health #Biotech #Crispr #GazeWire
Boehringer Ingelheim has committed up to $7.358 billion in a second major oncology collaboration with Sino Biopharmaceutical.
🔗 Read the full story on GazeWire
#Health #Biotech #Crispr #GazeWire
Nueve de cada diez veterinarios encuestados reconocen haber dejado algún servicio sin cobrar
Nueve de cada diez veterinarios encuestados reconocen haber dejado algún servicio sin cobrar
Boehringer Ingelheim ha organizado dos acciones formativas, en Bilbao y Alicante, para abordar un problema muy común en las clínicas veterinarias: gestionar correctamente el cobro de sus ser ...
mlibr.es
November 5, 2026 at 4:31 PM
Nueve de cada diez veterinarios encuestados reconocen haber dejado algún servicio sin cobrar
Boehringer Ingelheim: Cattle First Prevention Sweepstakes #contest #sweepstakes #giveaway
📅 Ends: February 4, 2027
✅ Entry Limit: Single
➡️ Enter Now: https://contestreminder.com/contest-138240/
🚨 Open to U.S. Residents
📅 Ends: February 4, 2027
✅ Entry Limit: Single
➡️ Enter Now: https://contestreminder.com/contest-138240/
🚨 Open to U.S. Residents
Win a Predator Inverter Generator
Enter the Boehringer Ingelheim Cattle First Prevention Sweepstakes for a chance to win a Predator Inverter Generator for your farm operations.
contestreminder.com
November 9, 2026 at 2:19 AM
Boehringer Ingelheim: Cattle First Prevention Sweepstakes #contest #sweepstakes #giveaway
📅 Ends: February 4, 2027
✅ Entry Limit: Single
➡️ Enter Now: https://contestreminder.com/contest-138240/
🚨 Open to U.S. Residents
📅 Ends: February 4, 2027
✅ Entry Limit: Single
➡️ Enter Now: https://contestreminder.com/contest-138240/
🚨 Open to U.S. Residents
Boehringer Ingelheim looks to Korean biotech for next drug breakthroughs
Boehringer Ingelheim looks to Korean biotech for next drug breakthroughs
Korea is moving beyond its traditional role as a market for medicines to become a source of pharmaceutical innovation, with local biotech partnerships and clini
www.koreaherald.com
November 3, 2026 at 5:31 PM
Boehringer Ingelheim looks to Korean biotech for next drug breakthroughs
Sino Biopharm Surges After Striking Over USD7 Billion Cancer Drug Deal With Boehringer Ingelheim www.yicaiglobal.com/news/sino-bi...
Sino Biopharm Surges After Striking Over USD7 Billion Cancer Drug Deal With Boehringer Ingelheim
www.yicaiglobal.com
November 5, 2026 at 3:35 AM
Sino Biopharm Surges After Striking Over USD7 Billion Cancer Drug Deal With Boehringer Ingelheim www.yicaiglobal.com/news/sino-bi...
Sino Biopharmaceutical said on Wednesday it had entered into an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate about $7 billion in milestone payments.
Sino Biopharmaceutical signs cancer deal worth about $7 billion with Germany's Boehringer
Sino Biopharmaceutical said on Wednesday it had entered into an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate about $7 billion in milestone payments.
reut.rs
November 4, 2026 at 9:00 AM
Sino Biopharmaceutical said on Wednesday it had entered into an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate about $7 billion in milestone payments.
Sino Biopharmaceutical signs cancer deal worth about $7 billion with Germany's Boehringer reut.rs/4ilJzfZ
Sino Biopharmaceutical signs cancer deal worth about $7 billion with Germany's Boehringer
Sino Biopharmaceutical said on Wednesday it had entered into an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate about $7 billion in milestone payments.
reut.rs
November 4, 2026 at 9:00 AM
Sino Biopharmaceutical signs cancer deal worth about $7 billion with Germany's Boehringer reut.rs/4ilJzfZ
Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs | #biotech #pharma #biotechsky
Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs
Boehringer Ingelheim has
www.fiercebiotech.com
November 6, 2026 at 6:30 PM
Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs | #biotech #pharma #biotechsky
"El reconocimiento de la profesión veterinaria sigue siendo una asignatura pendiente". La directora general de Boehringer Ingelheim Animal Health España analiza los grandes retos del sector
Elena Gratacós, directora general Boehringer Ingelheim Animal Health: "Es innegable que todavía existen obstáculos"
Elena Gratacós, directora general de Boehringer Ingelheim Animal Health España y presidenta de Veterindustria, analiza los cambios en la industria, el avance de la prevención y las necesidad ...
mlibr.es
October 31, 2026 at 9:02 PM
"El reconocimiento de la profesión veterinaria sigue siendo una asignatura pendiente". La directora general de Boehringer Ingelheim Animal Health España analiza los grandes retos del sector
Boehringer and Sino Biopharma Sign Cancer Research Deal With $358 Million in Initial Payments
Photo: Boehringer Ingelheim Boehringer Ingelheim and Sino Biopharmaceutical agreed Wednesday to develop six preclinical cancer-treatment programs, with SBP Group set to receive $358 million in upfront and…
Photo: Boehringer Ingelheim Boehringer Ingelheim and Sino Biopharmaceutical agreed Wednesday to develop six preclinical cancer-treatment programs, with SBP Group set to receive $358 million in upfront and…
Boehringer and Sino Biopharma Sign Cancer Research Deal With $358 Million in Initial Payments
Photo: Boehringer Ingelheim Boehringer Ingelheim and Sino Biopharmaceutical agreed Wednesday to develop six preclinical cancer-treatment programs, with SBP Group set to receive $358 million in upfront and near-term payments and potentially $7 billion more in option-exercise and milestone payments. The agreement is an option and license deal, not a $7 billion cash acquisition. The larger payments depend on future development, regulatory and commercial milestones, and none of the six programs is presented as an approved treatment.
jbiznews.com
November 4, 2026 at 8:29 PM
Boehringer and Sino Biopharma Sign Cancer Research Deal With $358 Million in Initial Payments
Photo: Boehringer Ingelheim Boehringer Ingelheim and Sino Biopharmaceutical agreed Wednesday to develop six preclinical cancer-treatment programs, with SBP Group set to receive $358 million in upfront and…
Photo: Boehringer Ingelheim Boehringer Ingelheim and Sino Biopharmaceutical agreed Wednesday to develop six preclinical cancer-treatment programs, with SBP Group set to receive $358 million in upfront and…
Boehringer Ingelheim signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical and its subsidiaries for experimental cancer treatments.
November 4, 2026 at 10:12 AM
Boehringer Ingelheim signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical and its subsidiaries for experimental cancer treatments.
Boehringer Ingelheim looks to Korean biotech for next drug breakthroughs
www.koreaherald.com/article/1092...
www.koreaherald.com/article/1092...
November 3, 2026 at 4:18 AM
Boehringer Ingelheim looks to Korean biotech for next drug breakthroughs
www.koreaherald.com/article/1092...
www.koreaherald.com/article/1092...
verloren haben.
Ingelheim hat in einem 1:1 2 Punkte liegen lassen, der FCK ist bisher noch ohne Punktverlust.
Ingelheim hat in einem 1:1 2 Punkte liegen lassen, der FCK ist bisher noch ohne Punktverlust.
November 1, 2026 at 10:15 PM
verloren haben.
Ingelheim hat in einem 1:1 2 Punkte liegen lassen, der FCK ist bisher noch ohne Punktverlust.
Ingelheim hat in einem 1:1 2 Punkte liegen lassen, der FCK ist bisher noch ohne Punktverlust.
Gut in den Event-Herbst gestartet? 🍂
Die Spiel '26 mag zu Ende sein, aber die nächsten Wochen haben noch einiges zu bieten! Los geht's mit den Ingelheimer Spieletagen am kommenden Wochenende (7.+8.11.).
Die Spiel '26 mag zu Ende sein, aber die nächsten Wochen haben noch einiges zu bieten! Los geht's mit den Ingelheimer Spieletagen am kommenden Wochenende (7.+8.11.).
November 4, 2026 at 8:22 AM
Gut in den Event-Herbst gestartet? 🍂
Die Spiel '26 mag zu Ende sein, aber die nächsten Wochen haben noch einiges zu bieten! Los geht's mit den Ingelheimer Spieletagen am kommenden Wochenende (7.+8.11.).
Die Spiel '26 mag zu Ende sein, aber die nächsten Wochen haben noch einiges zu bieten! Los geht's mit den Ingelheimer Spieletagen am kommenden Wochenende (7.+8.11.).
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody…
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody…
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in…
news-area.com
November 5, 2026 at 8:59 AM
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody…
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody…
Boehringer Ingelheim Licenses Six Cancer Programs From Sino Biopharm in Deal Worth Up to $7 Billion
Sino Biopharm receives $358 million in upfront and near-term payments for six preclinical antibody-drug conjugate and T-cell engager programs.
Sino Biopharm receives $358 million in upfront and near-term payments for six preclinical antibody-drug conjugate and T-cell engager programs.
Boehringer Ingelheim Licenses Six Cancer Programs From Sino Biopharm in Deal Worth Up to $7 Billion
Sino Biopharm receives $358 million in upfront and near-term payments for six preclinical antibody-drug conjugate and T-cell engager programs.
leprivatebanker.com
November 4, 2026 at 10:36 AM
Boehringer Ingelheim Licenses Six Cancer Programs From Sino Biopharm in Deal Worth Up to $7 Billion
Sino Biopharm receives $358 million in upfront and near-term payments for six preclinical antibody-drug conjugate and T-cell engager programs.
Sino Biopharm receives $358 million in upfront and near-term payments for six preclinical antibody-drug conjugate and T-cell engager programs.